Hallal David 4
4 · iTeos Therapeutics, Inc. · Filed Jun 6, 2025
Insider Transaction Report
Form 4
Hallal David
Director
Transactions
- Sale
Common Stock
2025-06-04$10.07/sh−38,227$384,946→ 0 total - Exercise/Conversion
Common Stock
2025-06-04$4.30/sh+38,227$164,376→ 38,227 total - Exercise/Conversion
Common Stock
2025-06-06$4.30/sh+38,228$164,380→ 38,228 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-06-04−38,227→ 76,455 totalExercise: $4.30From: 2022-07-01Exp: 2025-06-11→ Common Stock (38,227 underlying) - Sale
Common Stock
2025-06-06$10.24/sh−38,228$391,455→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-06-05−38,227→ 38,228 totalExercise: $4.30From: 2022-07-01Exp: 2025-06-11→ Common Stock (38,227 underlying) - Exercise/Conversion
Common Stock
2025-06-05$4.30/sh+38,227$164,376→ 38,227 total - Sale
Common Stock
2025-06-05$10.15/sh−38,227$388,004→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-06-06−38,228→ 0 totalExercise: $4.30From: 2022-07-01Exp: 2025-06-11→ Common Stock (38,228 underlying)
Footnotes (4)
- [F1]The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.01 to $10.16, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.09 to $10.22, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.19 to $10.29, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.